YARS2

Across TCGA pan-cancer cohorts, YARS2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of YARS2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where YARS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types YARS2 is over-expressed in tumor.

KIRC, KIRP, and BLCA are the cancer types where YARS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in YARS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	IV	+0.491	<.001	12	view →
KIRP	Female	II,III,IV	+1.309	<.001	11	view →
BLCA	Male	All	+1.056	<.001	11	view →
COAD	Female	II,III,IV	+0.981	<.001	11	view →
HNSC	Male	III,IV	+0.902	<.001	11	view →
LIHC	Female	II,III,IV	+1.060	<.001	9	view →
STAD	Male	II,III,IV	+0.905	<.001	9	view →
LUSC	Male	II,III,IV	+1.178	<.001	8	view →
LUAD	Male	II,III,IV	+1.026	<.001	8	view →
READ	All	All	+0.767	.002	7	view →
UCEC	All	II,III,IV	+0.983	<.001	6	view →
BRCA	All	III,IV	+0.474	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

YARS2–KIRC

Open the KIRC breakdown →